Ontrak (NASDAQ:OTRK – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Earnings and Valuation
This table compares Ontrak and Lisata Therapeutics' revenue, earnings per share and valuation.
Get Ontrak alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
Lisata Therapeutics has lower revenue, but higher earnings than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
49.8% of Ontrak shares are held by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are held by institutional investors. 46.6% of Ontrak shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.Profitability
This table compares Ontrak and Lisata Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ontrak | -279.90% | -183.58% | -92.71% |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Ontrak and Lisata Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Ontrak presently has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
Volatility and Risk
Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
Receive News & Ratings for Ontrak Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ontrak and related companies with MarketBeat.com's FREE daily email newsletter.